Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Overactive Bladder Syndrome: later-stage trial registry
8 of 13 indexed Overactive Bladder Syndrome trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #1,315 of 28,707 conditions by registered trial count.
13 US clinical trials · 8 currently recruiting · #1,315 of 28,707 conditions by registered trial count
Overactive Bladder Syndrome: 13 US clinical trials tracked, 8 recruiting.
Overactive Bladder Syndrome is the subject of 13 registered US clinical trials on ClinicalTrials.gov, 8 of them currently open to new participants. 6 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Novartis, running 1 of these trials.
Enrollment posture brief
Registry condition overactive-bladder-syndrome
OPEN 8 | RECR 62% | LATE 6 | EARLY 2 | RANK #1315 | SPON 1
Volume-matched condition peers
Nearest open-share peer: High Risk Myelodysplastic Syndrome (62% recruiting · 13 trials)
Overactive Bladder Syndrome lists 8 open slots (62% of 13 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Overactive Bladder Syndrome on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Overactive Bladder Syndrome is recruiting above its size-band peers.
8 of 13 indexed trials (61.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Overactive Bladder Syndrome trials is spread across many organizations.
Novartis accounts for 1 of 13 trials (7.7%). 13 distinct sponsors appear on at least one study for this condition label.
-
Typical Overactive Bladder Syndrome enrolment sits around 100 participants.
Median target enrolment is 100 among the 12 trials that report a genuine target (sentinel values excluded). 6 of those (50%) plan for fewer than 100 participants.
-
Overactive Bladder Syndrome research is mostly interventional.
13 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
13 total, page 1 of 1
BTL Emsella Chair Versus Sham for the Treatment of Overactive Bladder
Corewell Health East
NCT04873037
Vaginal Estradiol vs Oral Beta-3 Agonist for Overactive Bladder Syndrome
Walter Reed National Military Medical Center
NCT05221021
Oxybutynin for Post-surgical Bladder Pain and Urgency
University of California, Davis
NCT03952299
Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms
Northwestern University
NCT05878951
Testing MitoQ on Lower Urinary Tract Symptoms in Older Women With Metabolic Syndrome
Iman Al-Naggar, PhD
NCT06351683
Yoga for Treatment of Overactive Bladder in Pediatric Patients
Duke University
NCT05895045
Improving Overactive Bladder Treatment Access and Adherence
Stanford University
NCT06094543
rTMS in Overactive Bladder
The Methodist Hospital Research Institute
NCT06198439
Cyclic Versus Continuous Sacral Neuromodulation for LUTS
University Hospitals Cleveland Medical Center
NCT06170450
A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder.
Novartis
NCT00171145
Intradetrusor Botulinum Toxin A for OAB Via 1 Versus 10 Injections: A Randomized Clinical Trial
University of California, Irvine
NCT05308979
Prophylactic Antibiotic Administration for Bladder OnabotulinumtoxinA Injection
The Cleveland Clinic
NCT05719285
Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP584) for the Treatment of Overactive Bladder Syndrome
Pfizer
NCT00220376
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
| Phase 3 | 3 |
| Phase 4 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Overactive Bladder Syndrome records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Overactive Bladder Syndrome trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Overactive Bladder Syndrome page
13 registered trials, 8 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 8 Overactive Bladder Syndrome trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Novartis sponsors the most Overactive Bladder Syndrome trials on record, review their full trial history before evaluating a specific study. See Novartis's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Overactive Bladder Syndrome condition card totals 13 registered trials; most-linked intervention Darifenacin; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.